SNAI1 (Ab-246) Antibody

What is SNAI1 and what cellular functions does it regulate?

SNAI1 (Snail family transcriptional repressor 1) is a 29 kDa zinc finger protein that functions as a key transcriptional repressor involved in epithelial-to-mesenchymal transition (EMT). It plays critical roles in embryonic mesoderm formation and maintenance, growth arrest, survival, and cell migration. At the molecular level, SNAI1 binds to E-boxes of gene promoters (including E-cadherin/CDH1, CLDN7, and KRT8) and recruits histone demethylase KDM1A to decrease dimethylated H3K4 levels, thereby repressing transcription . During EMT, SNAI1 works with LOXL2 in regulating pericentromeric heterochromatin transcription, contributing to chromatin reorganization and acquisition of mesenchymal traits .

What is the significance of Ser246 phosphorylation in SNAI1 function?

Phosphorylation at Ser246 represents a critical post-translational modification that regulates SNAI1's activity and subcellular localization. Research indicates that SNAI1 undergoes a complex phosphorylation cascade where initial phosphorylation at certain sites (likely Ser-107, Ser-111, Ser-115, and Ser-119) triggers its export from the nucleus to the cytoplasm . Subsequently, phosphorylation at Ser246 and other sites in the destruction motif facilitates ubiquitination involving BTRC, affecting protein stability and function . This phosphorylation status directly impacts SNAI1's transcriptional repressor activity and its role in EMT regulation.

What are the typical applications for SNAI1 (phospho-Ser246) antibodies?

SNAI1 (phospho-Ser246) antibodies are validated for multiple experimental applications:

These antibodies specifically detect endogenous levels of SNAI1 only when phosphorylated at Ser246, making them valuable for studying the activated form of the protein .

How should I design experiments to study SNAI1 phosphorylation dynamics?

When studying SNAI1 phosphorylation dynamics:

• Time course experiments: Design experiments with multiple time points after stimulus application to capture the transient nature of phosphorylation events. SNAI1 phosphorylation status changes rapidly during cellular processes like EMT.

• Stimulus selection: Choose stimuli known to induce EMT or SNAI1 activity (TGF-β, EGF, hypoxia) based on your specific research questions.

• Subcellular fractionation: Since phosphorylation affects SNAI1's nuclear-cytoplasmic shuttling, include nuclear/cytoplasmic fractionation protocols before immunoblotting to track localization changes .

• Phosphatase inhibitors: Always include phosphatase inhibitors in lysis buffers to preserve phosphorylation status during sample preparation.

• Multiple phosphorylation site analysis: Consider examining other phosphorylation sites (Ser-107, Ser-111, Ser-115, Ser-119) alongside Ser246 to establish phosphorylation sequence and interdependence .

• Validation controls: Include phosphatase-treated samples as negative controls and samples from cells with constitutively active kinases as positive controls.

What cell models are most appropriate for studying SNAI1 (phospho-Ser246) in EMT research?

Based on validated research models:

• Cancer cell lines: Several epithelial cancer cell lines show robust SNAI1 expression and phosphorylation, including:

  • HeLa cells (validated for WB and IF applications)

  • MCF-7 breast cancer cells (validated for phospho-Ser246 studies)

  • Various gastrointestinal cancer models (STAD, COAD, READ) that show prognostic relevance of SNAI1 expression

• Normal cell models: 3T3 fibroblasts have been validated for SNAI1 (phospho-Ser246) antibody applications .

• Primary cells: Primary cells undergoing EMT, such as epithelial cells treated with TGF-β, can be valuable for physiologically relevant studies.

• Tissue samples: Human breast carcinoma tissue has been validated for IHC applications with phospho-Ser246 antibodies .

Choose cell models based on your specific research question, ensuring they express detectable levels of SNAI1 and relevant kinases/phosphatases that regulate Ser246 phosphorylation.

What are the critical steps for successful Western blotting using SNAI1 (phospho-Ser246) antibodies?

For optimal Western blot results with SNAI1 (phospho-Ser246) antibodies:

• Sample preparation:

  • Use phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers

  • Prepare fresh lysates; avoid repeated freeze-thaw cycles

  • Load 30-50 μg of total protein per lane

• Gel selection and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer to PVDF membranes (preferred over nitrocellulose for phosphoproteins)

• Blocking:

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

  • Block for 1 hour at room temperature or overnight at 4°C

• Antibody incubation:

  • Primary antibody dilution: 1:500-1:2000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle rocking

  • Secondary antibody: Use HRP-conjugated anti-rabbit IgG (1:5000-1:10000)

• Detection:

  • Use enhanced chemiluminescence (ECL) substrates; consider high-sensitivity ECL for low-abundance phosphoproteins

  • Expected molecular weight: 29-35 kDa

• Controls:

  • Include phosphatase-treated negative controls

  • Use SNAI1 knockout cell lysates as specificity controls

  • Consider using total SNAI1 antibody on parallel blots to normalize phosphorylation levels

How should I optimize immunofluorescence protocols for SNAI1 (phospho-Ser246) detection?

For optimal immunofluorescence results:

• Fixation:

  • 4% paraformaldehyde for 15 minutes at room temperature works well for SNAI1 phospho-epitope preservation

  • Avoid methanol fixation which can result in phospho-epitope loss

• Permeabilization:

  • Use 0.1-0.2% Triton X-100 for 5-10 minutes

  • Alternative: 0.5% saponin for gentler permeabilization

• Blocking:

  • 5% normal serum (from the species of secondary antibody) with 1% BSA

  • Include 0.1% Tween-20 to reduce background

• Antibody incubation:

  • Primary antibody dilution: 1:100-1:500 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • Secondary antibody: Use fluorophore-conjugated anti-rabbit IgG at 1:500-1:1000

• Counterstaining:

  • Nuclear counterstain with Hoechst 33342 or DAPI

  • Consider co-staining with total SNAI1 or other EMT markers

• Visualization:

  • SNAI1 (phospho-Ser246) localizes to both nucleus and cytoplasm

  • Use confocal microscopy for detailed subcellular localization studies

• Important controls:

  • Include secondary antibody-only controls

  • Use phosphatase-treated cells as negative controls

  • Consider siRNA knockdown cells for specificity validation

Why am I detecting multiple bands in Western blots with SNAI1 (phospho-Ser246) antibody?

Multiple bands when using SNAI1 (phospho-Ser246) antibody could result from:

• Post-translational modifications: SNAI1 undergoes multiple modifications (phosphorylation, ubiquitination, glycosylation) that can cause mobility shifts . The observed molecular weight range is typically 29-35 kDa .

• Proteolytic degradation: SNAI1 is subject to rapid turnover. Ensure complete protease inhibition during sample preparation.

• Cross-reactivity: Some antibodies may cross-react with related family members (SNAI2/Slug). Validate specificity using knockout or knockdown controls .

• Splice variants: Though less common for SNAI1, verify whether splice variants exist in your cell system.

Resolution approaches:

• Use freshly prepared samples with complete protease and phosphatase inhibitors

• Validate with knockout/knockdown controls

• Compare band patterns with different SNAI1 antibodies recognizing distinct epitopes

• Perform λ-phosphatase treatment to confirm phosphorylation-dependent bands

How can I improve signal-to-noise ratio in immunohistochemistry with SNAI1 (phospho-Ser246) antibody?

To improve signal-to-noise ratio in IHC applications:

• Antigen retrieval optimization:

  • Test multiple methods: citrate buffer (pH 6.0), EDTA buffer (pH 8.0-9.0), or enzymatic retrieval

  • Optimize retrieval time (10-30 minutes)

  • For phospho-epitopes, EDTA buffer (pH 8.0) often yields better results

• Blocking improvements:

  • Extend blocking time (1-2 hours)

  • Use 5-10% normal serum from secondary antibody species

  • Add 0.1% Triton X-100 to blocking solution

  • Consider avidin/biotin blocking if using biotin-based detection systems

• Antibody optimization:

  • Titrate antibody (1:50-1:200 range recommended)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use antibody diluent with background-reducing components

• Detection system selection:

  • Use polymer-based detection systems for reduced background

  • Consider tyramide signal amplification for low-abundance phosphoproteins

• Counterstaining and mounting:

  • Use lighter hematoxylin counterstaining to avoid masking specific signals

  • Mount with aqueous mounting media to preserve phospho-epitopes

• Validation controls:

  • Include tissue known to be positive/negative for phospho-SNAI1

  • Use phosphatase-treated sections as negative controls

How should I quantify and normalize SNAI1 (phospho-Ser246) levels in Western blot experiments?

For accurate quantification of phospho-SNAI1 levels:

• Normalization approaches:

  • Normalize phospho-SNAI1 to total SNAI1 on stripped and reprobed membranes or parallel blots (preferred method)

  • Use loading controls (β-actin, GAPDH) as secondary normalization

  • For nuclear/cytoplasmic fractions, use compartment-specific controls (Lamin B for nuclear, α-tubulin for cytoplasmic fractions)

• Quantification methods:

  • Use densitometry software (ImageJ, Image Lab, etc.)

  • Include a standard curve if absolute quantification is needed

  • Average multiple independent experiments (n≥3) for statistical validity

• Data presentation:

  • Report as ratio of phospho-SNAI1/total SNAI1

  • Present both representative blots and quantification graphs

  • Include statistical analysis (t-test, ANOVA) with appropriate p-values

• Considerations for time-course experiments:

  • Plot phosphorylation changes over time

  • Consider normalization to both baseline (time 0) and total protein

  • Account for changes in total SNAI1 levels which may also fluctuate

What are the implications of discrepancies between immunofluorescence and Western blot results for SNAI1 (phospho-Ser246)?

Discrepancies between immunofluorescence and Western blot results for phospho-SNAI1 can provide valuable insights:

• Subcellular localization differences:

  • Phosphorylation at Ser246 affects nuclear-cytoplasmic shuttling; IF can reveal spatial information missed in whole-cell lysate WBs

  • Consider performing subcellular fractionation before WB to align with IF observations

• Epitope accessibility differences:

  • Denaturation in WB may expose epitopes masked in IF

  • In IF, fixation methods can affect phospho-epitope accessibility

  • Try different fixation methods if discrepancies persist

• Threshold detection differences:

  • WB may detect population averages while IF shows cell-to-cell variability

  • Quantify IF signal intensity across multiple cells to better correlate with WB

• Resolution approaches:

  • Perform subcellular fractionation before WB

  • Use proximity ligation assays to validate phosphorylation-specific protein interactions

  • Consider complementary techniques like FACS analysis of phospho-proteins

  • Use phosphatase treatment controls in both techniques

How can I use SNAI1 (phospho-Ser246) antibody to investigate EMT in cancer progression models?

SNAI1 (phospho-Ser246) antibody can be leveraged for sophisticated EMT studies:

What experimental approaches can reveal the kinase-phosphatase regulatory network controlling SNAI1 Ser246 phosphorylation?

To decipher the regulatory network controlling SNAI1 Ser246 phosphorylation:

• Kinase identification strategies:

  • Perform in vitro kinase assays with recombinant SNAI1 and candidate kinases

  • Use kinase inhibitor panels to identify involved signaling pathways

  • Implement CRISPR/Cas9 screens targeting kinome members

  • Apply phosphoproteomics approaches to map kinase-substrate relationships

• Phosphatase identification approaches:

  • Use phosphatase inhibitors (okadaic acid, calyculin A) with varying specificities

  • Perform co-immunoprecipitation with phospho-SNAI1 to identify associated phosphatases

  • Express phosphatase catalytic and regulatory subunits to assess effects on Ser246 phosphorylation

• Spatial regulation analysis:

  • Investigate nuclear export mechanisms following phosphorylation

  • Examine the interplay between nuclear and cytoplasmic phosphatases

  • Use FRAP (Fluorescence Recovery After Photobleaching) to study phosphorylation-dependent mobility

• Context-dependent regulation:

  • Compare regulatory networks across different cell types and stimuli

  • Investigate cell cycle-dependent phosphorylation patterns

  • Examine the crosstalk between Ser246 and other phosphorylation sites (Ser-107, Ser-111, Ser-115, Ser-119)

How can phospho-specific SNAI1 antibodies contribute to understanding treatment resistance mechanisms?

SNAI1 (phospho-Ser246) antibodies can provide critical insights into treatment resistance:

• EMT-mediated therapy resistance:

  • Monitor phospho-SNAI1 levels before and after treatment in resistant vs. sensitive models

  • Correlate phosphorylation status with expression of drug transporters or anti-apoptotic proteins

  • Perform ChIP-seq with phospho-SNAI1 antibodies to identify resistance-associated target genes

• Combinatorial therapy approaches:

  • Test kinase inhibitors affecting SNAI1 phosphorylation in combination with conventional therapies

  • Use phospho-SNAI1 as a pharmacodynamic biomarker for EMT-targeting therapies

  • Develop patient stratification strategies based on phospho-SNAI1 status

• Liquid biopsy applications:

  • Explore detection of phospho-SNAI1 in circulating tumor cells as a resistance biomarker

  • Correlate with emergence of metastatic disease

  • Monitor therapy response longitudinally through minimally invasive sampling

What are the technical considerations for performing ChIP-seq using SNAI1 (phospho-Ser246) antibodies?

For successful ChIP-seq with phospho-specific SNAI1 antibodies:

• Crosslinking optimization:

  • Use dual crosslinking (DSG followed by formaldehyde) to better preserve protein-protein interactions

  • Optimize crosslinking time (10-15 minutes typically) to maintain phospho-epitope accessibility

• Chromatin preparation:

  • Include phosphatase inhibitors throughout all steps

  • Optimize sonication conditions for fragments of 200-300 bp

  • Pre-clear chromatin with protein A/G beads to reduce background

• Immunoprecipitation considerations:

  • Use higher antibody amounts than standard ChIP (5-10 μg per reaction)

  • Extend incubation time (overnight to 16 hours) at 4°C

  • Include IgG and total SNAI1 ChIP controls

  • Consider sequential ChIP (Re-ChIP) to identify genomic regions bound by specific phospho-forms

• Library preparation and sequencing:

  • Start with more input material due to potentially lower yields

  • Use spike-in controls for normalization

  • Consider deeper sequencing (>30 million reads) to capture transient or weak binding events

• Data analysis approaches:

  • Compare phospho-SNAI1 binding patterns with total SNAI1

  • Integrate with RNA-seq data to correlate binding with gene expression changes

  • Perform motif analysis to identify co-factors that may recognize phosphorylated SNAI1